# Safety, Pharmacokinetics (PK) of AKT and MEK Combination

> **NCT01138085** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 240 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK1120212
- **DRUG:** GSK2141795

## Key facts

- **NCT ID:** NCT01138085
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-04
- **Primary completion:** 2014-11-19
- **Final completion:** 2014-11-19
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01138085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01138085, "Safety, Pharmacokinetics (PK) of AKT and MEK Combination". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01138085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*